Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dean Rudge

Senior Reporter

London, UK

Dean has built up a wealth of knowledge on the global generics and biosimilar medicines industries in his five years with Generics bulletin. He specializes in commercial and legal issues, writing in-depth analyses of corporate strategy and getting under the skin of patent-infringement proceedings and other litigation. He attends investor and regulatory meetings with business leaders, favoring the investor days with their focus on corporate strategy. In his spare time, Dean enjoys visiting museums and playing five-a-side football.

Latest From Dean Rudge

US Court Dismisses Viatris EpiPen Suit, But Further Action Possible

US pharmacy KPH Healthcare Services, acting on behalf of purchasing giant McKesson, has seen an antitrust suit filed against Viatris’ Mylan and Pfizer dismissed, although the court said it would allow plaintiffs to come back with a further complaint.

Legal Issues Private Payers

Takeda Prevacid Suit Was Not A ‘Sham,’ US Court Tells Zydus Cadila

A US district court has denied Zydus Cadila’s motion for summary judgment on Sherman Act antitrust counterclaims against Takeda over a branded formulation of lansoprazole, finding that the originator did have basis to sue the ANDA sponsor again in 2018.

Intellectual Property Legal Issues

Jubilant To Reorganize With Generics API Business On The Move

Jubilant Pharmova – formerly Jubilant Life Sciences – plans to separate and move the active pharmaceutical ingredient business currently in the hands of its generic pharmaceuticals subsidiary, taking eventual control of the business itself.

M & A Strategy

UK Vaccines Business Pushes Wockhardt To Sales Growth

Having a year ago radically altered its business by offloading operations in India to rival Dr Reddy’s, India’s Wockhardt saw another burst of sales in the UK, amid its tie-up with AstraZeneca for the COVID-19 vaccine.

Coronavirus COVID-19 Sales & Earnings

Roche Battered By Biosimilars But Holds On To Initial Forecast

Roche insisted that “biosimilar competition is only one factor in the overall picture,” as it reported another set of depleted figures for its three powerhouse biologic brands: Avastin, MabThera/Rituxan and Herceptin.

Biosimilars Sales & Earnings

Sandoz Champions Stability As It Returns To Growth In Q2

Sandoz enjoyed both top- and bottom-line growth in the second quarter, as the Novartis company rebounded from a challenging Q1 and explained how it would reach its financial targets in the longer term.

Sales & Earnings Strategy
See All
UsernamePublicRestriction

Register